|
|
Volumn 4, Issue 5, 2005, Pages 367-368
|
|
Type 2 diabetes market
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2,4 THIAZOLIDINEDIONE DERIVATIVE;
ACARBOSE;
ALPHA GLUCOSIDASE INHIBITOR;
BIGUANIDE DERIVATIVE;
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
EXENDIN 4;
GLIPIZIDE;
GLUCAGON LIKE PEPTIDE 1 DERIVATIVE;
INSULIN;
LIRAGLUTIDE;
MEGLITINIDE;
METFORMIN;
MURAGLITAZAR;
NEW DRUG;
ORAL ANTIDIABETIC AGENT;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;
PIOGLITAZONE;
RIMONABANT;
ROSIGLITAZONE;
SITAGLIPTIN;
SULFONYLUREA;
TROGLITAZONE;
UNCLASSIFIED DRUG;
VILDAGLIPTIN;
BODY WEIGHT DISORDER;
CARCINOGENESIS;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG MARKETING;
DRUG MECHANISM;
DRUG SYNTHESIS;
DRUG WITHDRAWAL;
EDEMA;
GASTROINTESTINAL SYMPTOM;
HEALTH CARE COST;
HUMAN;
HYPERLIPIDEMIA;
HYPOGLYCEMIA;
INSULIN RESISTANCE;
LACTIC ACIDOSIS;
LIVER TOXICITY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NOTE;
OBESITY;
PATENT;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
WEIGHT GAIN;
DIABETES MELLITUS, TYPE 2;
DRUG INDUSTRY;
HUMANS;
HYPOGLYCEMIC AGENTS;
|
|
EID: 18944371703
PISSN: 14741776
EISSN: None
Source Type: Journal
DOI: 10.1038/nrd1723 Document Type: Note |
|
Times cited : (66)
|
|
References (2)
|
